



## **Amifampridine (Firdapse®)**

**BioMarin Europe Ltd**

**March 2010**

### **Advisory notice to NHS Wales**

**Amifampridine (Firdapse®) has not been endorsed for use within NHS Wales for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)**

**The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of amifampridine (Firdapse®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.**

AWMSG takes into account the NICE future work programme when considering whether a product will be appraised. To avoid duplication of effort, AWMSG would not normally consider undertaking an appraisal if NICE intend to publish final advice of the same product within twelve months of the projected Form B submission date. AWMSG advice is interim to that of NICE, should NICE subsequently publish guidance.

This notice is provided for information to NHS Wales. In the absence of guidance issued by NICE or AWMSG, clinicians should continue to exercise their clinical judgement when providing care for an individual patient. This should be in consultation with the patient and/or guardian or carer, based on the best available evidence.

This notice will be removed on receipt of a full submission (i.e. Form A and B) or when final NICE guidance becomes available.